Showing results (1311-1320 of 1,349) with videos related to
Sort By:
Pageof 135
BMJ Open|March 27, 2021
Clinical and cost-effectiveness of bracing in symptomatic knee osteoarthritis management: protocol for a multicentre, primary care, randomised, parallel-group, superiority trialMelanie A Holden, Michael Callaghan, David Felson, et al.The Pediatric Infectious Disease Journal|February 25, 2025
Plasma Microbial Cell-free DNA Sequencing for the Detection of Kingella kingae Pediatric Spinal InfectionsAsim A Ahmed, Sarah Y Park, Matthew J Smollin, et al.Journal of the American College of Cardiology|July 18, 2000
Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional studyT P Graham, Y D Bernard, B G Mellen, et al.Pain|December 2, 2017
Core outcome measurement instruments for clinical trials in nonspecific low back painAlessandro Chiarotto, Maarten Boers, Richard A Deyo, et al.Trials|December 27, 2014
A core outcome set for clinical trials on non-specific low back pain: study protocol for the development of a core domain setAlessandro Chiarotto, Caroline B Terwee, Richard A Deyo, et al.European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society|April 6, 2015
Core outcome domains for clinical trials in non-specific low back painAlessandro Chiarotto, Richard A Deyo, Caroline B Terwee, et al.Nature|January 10, 2024
MRE11 liberates cGAS from nucleosome sequestration during tumorigenesisMin-Guk Cho, Rashmi J Kumar, Chien-Chu Lin, et al.Nature Immunology|June 9, 2016
Control of the innate immune response by the mevalonate pathwayMurali K Akula, Man Shi, Zhaozhao Jiang, et al.NIHR Open Research|June 9, 2025
Clinical and cost-effectiveness of individualised exercises and foot orthoses in the treatment of plantar heel pain: protocol for the TREADON randomised multi-arm multi-stage adaptive trialMartin J Thomas, Gemma Hughes, Kendra Cooke, et al.Annals of the Rheumatic Diseases|October 1, 2018
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trialsNicolino Ruperto, Hermine I Brunner, Pierre Quartier, et al.Pageof 135